https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
Russia News
27.04.2020

Russia News

At the current stage, we are facing an unsure situation with diverging movements. On one hand, the nationwide vacation is expected to be...
Read more
Taplow News- 2nd Pandemic Business Overview
20.04.2020

Taplow News- 2nd Pandemic Business Overview

Taplow Group – Pandemic Business OverviewThe global pandemic has seen businesses affected across every sector, in all parts of the world....
Read more
Navigating the Post Pandemic World Order - Our Take
16.04.2020

Navigating the Post Pandemic World Order - Our Take

As the world battles Covid-19, countries have triggered containment measures that have half of humanity in lock down. Not to mention the economic...
Read more
First10111213141516171819Last

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers

  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here

  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here

  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here

  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here